125 related articles for article (PubMed ID: 15193996)
21. FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity.
Mencarelli A; Cipriani S; Renga B; D'Amore C; Palladino G; Distrutti E; Baldelli F; Fiorucci S
Nutr Metab Cardiovasc Dis; 2013 Feb; 23(2):94-101. PubMed ID: 21924881
[TBL] [Abstract][Full Text] [Related]
22. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism.
Ljungberg A; Lindén D; Améen C; Bergström G; Oscarsson J
Growth Horm IGF Res; 2007 Apr; 17(2):154-64. PubMed ID: 17307376
[TBL] [Abstract][Full Text] [Related]
23. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.
Ding SY; Shen ZF; Chen YT; Sun SJ; Liu Q; Xie MZ
Acta Pharmacol Sin; 2005 May; 26(5):575-80. PubMed ID: 15842776
[TBL] [Abstract][Full Text] [Related]
24. Using laser scanning cytometry to measure PPAR-mediated peroxisome proliferation and beta oxidation.
Pruimboom-Brees IM; Brees DJ; Shen AC; Keener M; Francone O; Amacher DE; Loy JK; Kerlin RL
Toxicol Pathol; 2005; 33(1):86-91. PubMed ID: 15805059
[TBL] [Abstract][Full Text] [Related]
25. Tryptophan-NAD+ pathway metabolites as putative biomarkers and predictors of peroxisome proliferation.
Delaney J; Hodson MP; Thakkar H; Connor SC; Sweatman BC; Kenny SP; McGill PJ; Holder JC; Hutton KA; Haselden JN; Waterfield CJ
Arch Toxicol; 2005 Apr; 79(4):208-23. PubMed ID: 15838709
[TBL] [Abstract][Full Text] [Related]
26. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
[TBL] [Abstract][Full Text] [Related]
27. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis.
Hays T; Rusyn I; Burns AM; Kennett MJ; Ward JM; Gonzalez FJ; Peters JM
Carcinogenesis; 2005 Jan; 26(1):219-27. PubMed ID: 15447978
[TBL] [Abstract][Full Text] [Related]
28. PPARalpha activators may be good candidates as antiaging agents.
Erol A
Med Hypotheses; 2005; 65(1):35-8. PubMed ID: 15893114
[TBL] [Abstract][Full Text] [Related]
29. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
30. Cevoglitazar, a novel peroxisome proliferator-activated receptor-alpha/gamma dual agonist, potently reduces food intake and body weight in obese mice and cynomolgus monkeys.
Chen H; Dardik B; Qiu L; Ren X; Caplan SL; Burkey B; Boettcher BR; Gromada J
Endocrinology; 2010 Jul; 151(7):3115-24. PubMed ID: 20484464
[TBL] [Abstract][Full Text] [Related]
31. (+)-Z-Bisdehydrodoisynolic acid ameliorates obesity and the metabolic syndrome in female ZDF rats.
Banz WJ; Davis J; Steinle JJ; Adler S; Oitker J; Winters TA; Higginbotham DA; Hou Y; Henry N; Peterson R; Meyers CY
Obes Res; 2005 Nov; 13(11):1915-24. PubMed ID: 16339123
[TBL] [Abstract][Full Text] [Related]
32. Beta-cell function and mass in type 2 diabetes.
Larsen MO
Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
[TBL] [Abstract][Full Text] [Related]
33. 18F9 (4-(3,6-bis (ethoxycarbonyl)-4,5,6,7-tetrahydrothieno (2,3-c) pyridin-2-ylamino)-4-oxobutanoic acid) enhances insulin-mediated glucose uptake in vitro and exhibits antidiabetic activity in vivo in db/db mice.
Anandharajan R; Sayyed SG; Doshi LS; Dixit P; Chandak PG; Dixit AV; Brahma MK; Deshmukh NJ; Gupte R; Damre A; Suthar J; Padigaru M; Sharma SD; Nemmani KV
Metabolism; 2009 Oct; 58(10):1503-16. PubMed ID: 19608207
[TBL] [Abstract][Full Text] [Related]
34. Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys.
Gee MK; Zhang L; Rankin SE; Collins JN; Kauffman RF; Wagner JD
Metabolism; 2004 Sep; 53(9):1121-5. PubMed ID: 15334371
[TBL] [Abstract][Full Text] [Related]
35. A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet.
Tsunoda M; Kobayashi N; Ide T; Utsumi M; Nagasawa M; Murakami K
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E833-40. PubMed ID: 18212024
[TBL] [Abstract][Full Text] [Related]
36. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
[TBL] [Abstract][Full Text] [Related]
37. Reduction of all-trans-retinal in the mouse liver peroxisome fraction by the short-chain dehydrogenase/reductase RRD: induction by the PPAR alpha ligand clofibrate.
Lei Z; Chen W; Zhang M; Napoli JL
Biochemistry; 2003 Apr; 42(14):4190-6. PubMed ID: 12680773
[TBL] [Abstract][Full Text] [Related]
38. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
[TBL] [Abstract][Full Text] [Related]
39. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
[TBL] [Abstract][Full Text] [Related]
40. Salacia oblonga root improves postprandial hyperlipidemia and hepatic steatosis in Zucker diabetic fatty rats: activation of PPAR-alpha.
Huang TH; Peng G; Li GQ; Yamahara J; Roufogalis BD; Li Y
Toxicol Appl Pharmacol; 2006 Feb; 210(3):225-35. PubMed ID: 15975614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
